CRISPR Therapeutics AG (NASDAQ:CRSP) COO Sells $50,819.16 in Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) COO Julianne Bruno sold 1,198 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $50,819.16. Following the sale, the chief operating officer now directly owns 8,263 shares in the company, valued at approximately $350,516.46. This trade represents a 12.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

CRISPR Therapeutics Trading Up 0.3 %

NASDAQ:CRSP opened at $42.12 on Friday. CRISPR Therapeutics AG has a 1 year low of $36.52 and a 1 year high of $75.91. The firm has a 50 day moving average of $43.06 and a 200-day moving average of $45.58. The stock has a market capitalization of $3.61 billion, a P/E ratio of -9.64 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Capital Market Strategies LLC bought a new position in CRISPR Therapeutics in the 4th quarter worth approximately $461,000. KBC Group NV raised its position in CRISPR Therapeutics by 2,047.4% in the 4th quarter. KBC Group NV now owns 60,514 shares of the company’s stock worth $2,382,000 after purchasing an additional 57,696 shares during the last quarter. Geode Capital Management LLC raised its position in CRISPR Therapeutics by 3.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock worth $47,383,000 after purchasing an additional 35,196 shares during the last quarter. State Street Corp raised its position in CRISPR Therapeutics by 25.0% in the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after purchasing an additional 599,304 shares during the last quarter. Finally, ARK Investment Management LLC raised its position in CRISPR Therapeutics by 19.7% in the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock worth $353,180,000 after purchasing an additional 1,474,439 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CRSP. Chardan Capital decreased their target price on CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a research report on Wednesday, February 19th. Barclays lifted their target price on CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 12th. Evercore ISI raised CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and lifted their price objective for the company from $60.00 to $99.00 in a report on Friday, February 14th. Finally, Royal Bank of Canada decreased their price objective on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $73.11.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.